Clinical Case Reports (Jun 2021)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome

  • Satoko Oka,
  • Kazuo Ono

DOI
https://doi.org/10.1002/ccr3.4287
Journal volume & issue
Vol. 9, no. 6
pp. n/a – n/a

Abstract

Read online

Abstract Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.

Keywords